Although cCMV is the leading non-genetic cause of childhood hearing loss in the United States, neither targeted nor universal screening protocols have been well established to identify cCMV in newborns. Moreover, until cCMV testing is universal, clinical protocols need to account for the complexities of individualized care in partnership with interprofessional care teams. This work addressed an immediate clinical practice need to identify cCMV with subsequent hearing monitoring of babies who test positive for cCMV. This effort focused on three primary objectives to: 1) define interprofessional, team-based approach to facilitate care pathways; 2) develop a clinical workflow for all babies who refer on inpatient hearing screening to be tested for cCMV by 21 days of age; 3) develop a hearing monitoring plan for all babies who test positive for cCMV. The development and integration of our interprofessional, team-based approach to institute cCMV testing by 21 days of age on all babies who refer inpatient newborn hearing screening and subsequent monitoring is described. Our observed referral rate was lower than predicted (2.7%) from existing literature with only one positive cCMV outcome noted in the two-year span. This study demonstrates the feasibility of a hearing-targeted cCMV testing paradigm in our clinic practice.
Martin, J. R. Huskins, W. Schimmenti, L. A. Cofer, S. A. & Poling, G. L. (2021). Advancing Clinical Practice through Integration of Congenital Cytomegalovirus (cCMV) Testing with Newborn Hearing Screening at Mayo Clinic. Journal of Early Hearing Detection and Intervention, 6(2), 28-38. DOI: https://doi.org/10.26077/3611-b6db
Retrieved from https://digitalcommons.usu.edu/jehdi/vol6/iss2/4